养心定悸胶囊治疗冠心病的疗效及对心血管事件的影响

Curative Efficacy of Yangxin Dingji Capsule in Treatment of Coronary Heart Disease and Effects on Cardiovascular Events

目的:观察养心定悸胶囊治疗冠心病的疗效及对心血管事件的影响。方法:选择2015-06—2017-06本院接诊的96例冠心病患者作为研究对象,通过随机数表法分为观察组(n=48)和对照组(n=48),对照组给予西医常规治疗,观察组在对照组基础上联合养心定悸胶囊治疗,均连续治疗1个月后比较两组临床疗效、中医症候积分、颈动脉斑块形态的变化和不良反应、半年内不良心血管事件发生率。结果:治疗1个月后,观察组临床疗效总有效率明显高于对照组(91.67%vs 72.92%,P<0.05);两组胸闷、心悸、气短症候积分较治疗前均明显降低(P<0.01),且观察组较对照组降低更明显(P<0.01);两组斑块数量、斑块面积、颈动脉内膜中膜厚度(IMT)较治疗前明显改善(P<0.01),且观察组改善程度优于对照组(P<0.01);两组治疗期间不良反应总发生率差异无统计学意义(8.33%vs 12.50%,P>0.05);观察组心律失常、心肌梗死、心力衰竭、急性冠脉综合征等心血管事件总发生率为明显低于对照组(9.09%vs 26.09%,P<0.05)。结论:养心定悸胶囊联合西医治疗冠心病疗效显著,且可降低心血管事件发生率,值得推广应用。

Objective： To study curative efficacy of Yangxin dingji capsule in treatment of coronary heart disease and effects on cardiovascular events Method： 96 patients of coronary heart disease who received therapy from June 2015 to June 2017 in our hospital were selected as research objects, according to random number table, those patients were divided into the observation group （ n =48） and the control group （ n =48）, the control group was treated with routine treatment, while the observation group was treated with Yangxin dingji capsule, they were treated continuously for 1 months. The clinical efficacy, TCM syndrome score, carotid atherosclerotic plaques, adverse reactions and incidence of adverse cardiovascular events in two groups was compared. Results： After the end of treatment, the total effective rate of the observation group was significantly higher than those in the control group（91.67% vs 72.92%, P 〈0.05）.The symptoms of chest tightness, palpitation and shortness of breath in the two groups were significantly lower than those before treatment（ P 〈0.01）, the symptoms of chest tightness, palpitation and shortness of breath in the observation group were significantly lower than those in the control group（ P 〈0.01）.The plaque number, plaque area and carotid intima media thickness （IMT） of the two groups were significantly different from those before treatment（ P 〈0.01）, the plaque number, plaque area and IMT in the observation group were significantly lower than those in the control group（ P 〈0.01）.The total incidence of adverse reactions in the two groups was no significant difference（8.33% vs 12.50%, P 〉0.05）. The total incidence of arrhythmia,myocardial infarction, heart failure and acute coronary syndrome in the observation group were lower than those in the control group（9.09% vs 26.09%, P 〈0.05）. Conclusion： Yangxin dingji capsule is well for coronary heart disease, which helps to reduce the incidence of cardiovascular events, and has high safety, it＇s worthy of application and promotion.